Oral JAK inhibitor promising in refractory RA


A novel oral JAK inhibitor has shown promise in patients with rheumatoid arthritis who have failed to respond to other treatments, the results of a phase III trial show. The 24-week double blind placebo-controlled trial involved 527 patients with an inadequate response to one or more TNF inhibitors who were randomised to receive 2mg or ...


Already a member? Login to keep reading


OR
© 2017 the limbic